

In the Specification:

Please amend the specification as indicated below. A "Version With Marking to Show Changes Made to the Specification and the Abstract of the Disclosure" is presented in Appendix A.

*Changed
for
claim*

One the first page, please replace the title with the following:

METHODS FOR INHIBITING THE INTERACTION OF B7-2 WITH ITS NATURAL
LIGAND

On the first page, please replace the paragraph under the heading "Related Applications", with the following paragraph:

DI
This application is a continuation application of U.S. Serial No. 08/479,744, filed on June 5, 1995, now U.S. Patent 6,084,067, which is a continuation-in-part of U.S. Serial No. 08/280,757, entitled "Novel CTLA4/CD28 Ligands and Uses Therefor" filed July 26, 1994, now U.S. Patent No. 6,130,316, which is a continuation-in-part of U.S. Serial No. 08/109,393, entitled "Novel CTLA4/CD28 Ligands and Uses Therefor" filed August 19, 1993, pending, which is a continuation-in-part of U.S. Serial No. 08/101,624, also entitled "Novel CTLA4/CD28 Ligands and Uses Therefor", filed July 26, 1993, now U.S. Patent No. 5,942,607. U.S. Serial No. 08/479,744, now U.S. Patent No. 6,084,067, is also a continuation-in-part of U.S. Serial No. 08/147,773, entitled "Tumor Cells Modified To Express B7-2 And B7-3 With Increased Immunogenicity And Uses Therefor" filed November 3, 1993, now abandoned. The contents of each of these applications is incorporated herein by reference.